Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG studyShaji Kumar, B G M Durie, Meletios Α. Dimopoulos et al.|Leukemia|2017Cited by 356
Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidityRebecca Elstrom, Usama Gergis, Peter Martin et al.|American Journal of Hematology|2011Cited by 42
Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple MyelomaSathish Gopalakrishnan, Parameswaran Hari, Bipin N. Savani et al.|Transplantation and Cellular Therapy|2018Cited by 28
Milatuzumab: a promising new agent for the treatment of lymphoid malignanciesTomer M. Mark, Rubén Niesvizky, Peter Martin et al.|Expert Opinion on Investigational Drugs|2008Cited by 25
Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between GroupsEmma C. Scott, Anita D’Souza, Parameswaran Hari et al.|Transplantation and Cellular Therapy|2018Cited by 14